Group 1 - The company Wangshan Wangshui-B (02630) has completed its subscription period from October 28 to November 3, 2025, with a total margin loan of at least HKD 279.7 billion, resulting in an oversubscription of 4,974 times against the public offering amount of HKD 59.83 million [1] - The company plans to issue 17.6 million shares, with 10% allocated for public offering, and the share price is set between HKD 32 to 34, aiming to raise up to nearly HKD 600 million [1][2] - Wangshan Wangshui is a biopharmaceutical company established in 2013, focusing on discovering, acquiring, developing, and commercializing small molecule drugs in strategic therapeutic areas, specifically neuropsychiatric and reproductive health [1] Group 2 - The company has not yet achieved profitability, recording a net loss of RMB 218 million in 2024, compared to a net profit of RMB 6.427 million in 2023, with the fluctuation attributed to a decline in revenue [2] - According to the prospectus, 38% of the net proceeds from the global offering will be allocated to the research and development of core products, 27% for other candidate products, 15% to enhance sales and marketing capabilities, 10% for building a factory in Qingdao, and 10% for other general corporate purposes [2]
新股消息 | 旺山旺水-B(02630)招股结束 孖展认购额达2797亿港元 超购4974倍